1. Home
  2. KELYA vs MGNX Comparison

KELYA vs MGNX Comparison

Compare KELYA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kelly Services Inc.

KELYA

Kelly Services Inc.

N/A

Current Price

$15.88

Market Cap

340.1M

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

N/A

Current Price

$4.00

Market Cap

280.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KELYA
MGNX
Founded
1946
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
340.1M
280.3M
IPO Year
1994
2013

Fundamental Metrics

Financial Performance
Metric
KELYA
MGNX
Price
$15.88
$4.00
Analyst Decision
Buy
Buy
Analyst Count
1
5
Target Price
$15.00
$5.00
AVG Volume (30 Days)
267.7K
478.2K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
3.07%
N/A
EPS Growth
N/A
N/A
EPS
0.15
N/A
Revenue
$5,355,600,000.00
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.60
$3.19
P/E Ratio
$106.40
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.98
$1.30
52 Week High
$17.75
$5.08

Technical Indicators

Market Signals
Indicator
KELYA
MGNX
Relative Strength Index (RSI) 46.63 45.32
Support Level $14.53 $3.83
Resistance Level $16.50 $4.38
Average True Range (ATR) 0.49 0.20
MACD -0.21 0.00
Stochastic Oscillator 14.04 13.33

Price Performance

Historical Comparison
KELYA
MGNX

About KELYA Kelly Services Inc.

Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: